PODD · News · 20260805N
Guidance and Outlook
INSULET CORP · 2026-08-05 · Importance 83 · Surprise 92 · In source text
Insulet lowered its fiscal 2026 GAAP revenue growth guidance to 21%–23% because of a softer second half, particularly for U.S. Omnipod sales. The company reduced its full-year U.S. revenue-growth outlook to 17%–19% from 20%–22%. Third-quarter revenue guidance of $833.4 million was below analyst expectations. Insulet raised adjusted EPS growth guidance to more than 30% for 2026 despite the revenue outlook reduction.
Key facts
- Next quarter revenue guidance of $833.4 million was reported to fall below analyst expectations. source
- Insulet lowered its annual sales growth forecast citing a softer second half of 2026 particularly for U.S. sales of its Omnipod insulin pumps. source
- Insulet's stock tumbled 12.1% after Q2 2026 results due to a meaningful cut in its full-year revenue growth forecast and weaker Type 2 retention. source
- One report said shares fell more than 12% before the bell after Insulet lowered its annual sales growth forecast. source
- Oppenheimer downgraded Insulet from Outperform to Perform on August 5, 2026. source
- Truist Securities downgraded Insulet from Buy to Hold and set a new price target of $153.00. source
- Stifel lowered its price target for Insulet to $180.00 from $225.00. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | committed | — | Next quarter revenue guidance of $833.4 million was reported to fall below analyst expectations. |
| revenue | negative | committed | — | Insulet lowered its annual sales growth forecast citing a softer second half of 2026 particularly for U.S. sales of its Omnipod insulin… |